Unveils TriCell, NovaStem, ReWave, and Brifill in Dubai
(Image provided by REV-MED)
[The Power News | Reporter Min Jin]
REV-MED participated in the Arab Health 2025 exhibition held from January 27 to 30 at the Dubai World Trade Centre in the United Arab Emirates (UAE). The event is one of the largest international medical device exhibitions in the Middle East.
At the exhibition, REV-MED showcased its TriCell and NovaStem product lines, featuring technology capable of extracting platelets, CD34+ cells, T-cells, and other immune cells from blood. The company also introduced its ReWave, a skin regeneration device utilizing ultra-high-frequency microwave technology, and Brifill, an HA filler, broadening its aesthetic product portfolio.
A REV-MED global affairs representative stated,
"We are the only Korean company in the field of multi-cell extraction from blood to have obtained regulatory approvals from both Japan's PMDA and China's NMPA—proving the excellence of K-bio technology."
The representative added,
"As a leader in the emerging biologics sector of the global biotech market, we will continue to drive innovation and R&D to expand into every category of regenerative medicine."
Source: The Power News
(Image provided by REV-MED)
[The Power News | Reporter Min Jin]
REV-MED participated in the Arab Health 2025 exhibition held from January 27 to 30 at the Dubai World Trade Centre in the United Arab Emirates (UAE). The event is one of the largest international medical device exhibitions in the Middle East.
At the exhibition, REV-MED showcased its TriCell and NovaStem product lines, featuring technology capable of extracting platelets, CD34+ cells, T-cells, and other immune cells from blood. The company also introduced its ReWave, a skin regeneration device utilizing ultra-high-frequency microwave technology, and Brifill, an HA filler, broadening its aesthetic product portfolio.
A REV-MED global affairs representative stated,
"We are the only Korean company in the field of multi-cell extraction from blood to have obtained regulatory approvals from both Japan's PMDA and China's NMPA—proving the excellence of K-bio technology."
The representative added,
"As a leader in the emerging biologics sector of the global biotech market, we will continue to drive innovation and R&D to expand into every category of regenerative medicine."
Source: The Power News